Sysmex (OTCMKTS:SSMXY) Trading Down 4.6% – Should You Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) traded down 4.6% during mid-day trading on Wednesday . The company traded as low as $8.70 and last traded at $8.70. 200 shares traded hands during trading, a decline of 100% from the average session volume of 259,757 shares. The stock had previously closed at $9.12.

Analyst Upgrades and Downgrades

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Sysmex Trading Up 0.2%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The company’s 50 day moving average is $8.74 and its two-hundred day moving average is $9.17. The firm has a market cap of $5.70 billion, a P/E ratio of 23.83 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.28%. The company had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, sell-side analysts predict that Sysmex Corporation ADR will post 0.37 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.